{"title":"管理病毒性丙型肝炎:新机遇，高成本两种新的生物制剂建立了更高的护理标准。然而，管理这些代理将是非常复杂的。","authors":"Jennifer Cawood","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Two new biologics for HCV present treatment and cost-management challenges.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 3","pages":"26-8"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278124/pdf/bh0803026.pdf","citationCount":"0","resultStr":"{\"title\":\"Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher standard of care. Managing these agents, however, will be highly complex.\",\"authors\":\"Jennifer Cawood\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Two new biologics for HCV present treatment and cost-management challenges.</p>\",\"PeriodicalId\":89534,\"journal\":{\"name\":\"Biotechnology healthcare\",\"volume\":\"8 3\",\"pages\":\"26-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278124/pdf/bh0803026.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology healthcare\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher standard of care. Managing these agents, however, will be highly complex.
Two new biologics for HCV present treatment and cost-management challenges.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
